• Molecular NameMesalazine
  • Synonym5-aminosalicylate; 5-aminosalicylic acid; 5-ASA; Mesalamine
  • Weight153.137
  • Drugbank_IDDB00244
  • ACS_NO89-57-6
  • Show 3D model
  • LogP (experiment)0.89
  • LogP (predicted, AB/LogP v2.0)1.41
  • pkaN/A
  • LogD (pH=7, predicted)-1.81
  • Solubility (experiment)0.84 mg/ml
  • LogS (predicted, ACD/Labs)(ph=7)-0.91
  • LogSw (predicted, AB/LogsW2.0)1.83
  • Sw (mg/ml) (predicted, ACD/Labs)0.58
  • No.of HBond Donors4
  • No.of HBond Acceptors4
  • No.of Rotatable Bonds1
  • TPSA83.55
  • StatusFDA approved
  • Administrationoral, rectal
  • PharmacologyAn anti-inflammatory drug used to treat inflammation of the digestive tract ulcerative colitis[1] and mild to moderate Crohn's disease.
  • Absorption_value25.0
  • Absorption (description)N/A
  • Caco_2N/A
  • BioavailabilityN/A
  • Protein binding50.0
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmRapidly & extensively metabolised intestinal mucosal wall and the liver
  • Half life7 h
  • ExcretionN/A
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityThere have been no documented reports of serious toxicity in man resulting from massive overdosing with mesalamine. Under ordinary circumstances, mesalamine absorption from the colon is limited.
  • LD50 (rat)LD50=2800 mg/kg
  • LD50 (mouse)LD50=3370 mg/kg